

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Base-Modified Purine 2',3'-Dideoxyribonucleosides: Synthesis via Deoxygenation or Direct Nucleobase Anion Glycosylation

F. Seela^a; H. Rosemeyer^a; R. Gumbiowski^a; K. Mersmann^a; H.-P. Muth^a; A. Röling^a

^a Laboratorium für Organische und Bioorganische Chemie, Fachbereich Biologie/Chemie, Universität Osnabrück, Osnabrück

To cite this Article Seela, F. , Rosemeyer, H. , Gumbiowski, R. , Mersmann, K. , Muth, H.-P. and Röling, A.(1991) 'Base-Modified Purine 2',3'-Dideoxyribonucleosides: Synthesis via Deoxygenation or Direct Nucleobase Anion Glycosylation', *Nucleosides, Nucleotides and Nucleic Acids*, 10: 1, 409 — 412

To link to this Article: DOI: 10.1080/07328319108046490

URL: <http://dx.doi.org/10.1080/07328319108046490>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

BASE-MODIFIED PURINE 2',3'-DIDEOXYRIBONUCLEOSIDES: SYNTHESIS VIA DEOXYGENATION OR DIRECT NUCLEOBASE ANION GLYCOSYLATION

F. Seela*, H. Rosemeyer, R. Gumbiowski, K. Mersmann, H.-P. Muth, and A. Rölting


Laboratorium für Organische und Bioorganische Chemie, Fachbereich Biologie/Chemie, Universität
Osnabrück, Barbarastr. 7, D-4500 Osnabrück

Abstract: 5-Aza-7-deazapurine, 5-aza-1,7-dideazapurine, and 8-azapurine 2',3'-dideoxy-D-ribonucleosides have been synthesized and inhibitory activity against HIV reverse transcriptase and DNA-polymerases has been evaluated.


Purine- and pyrimidine 2',3'-dideoxynucleosides show antiviral activity against human immunodeficiency virus (HIV).¹ Permeation through the cell membrane, phosphorylation at OH-5', and metabolic stability are necessary for their use as drugs during treatment of AIDS. Moreover, a high selectivity index of the corresponding triphosphates between HIV reverse transcriptase and DNA polymerases is required.

In the following we report on the synthesis of base-modified 2',3'-dideoxyribonucleosides (5-aza-7-deazapurine and 5-aza-1,7-dideazapurine as well as 8-azapurine and 7-deazapurine 2',3'-dideoxyribofuranosides). Moreover, inhibitory data of corresponding triphosphates against HIV reverse transcriptase (RT) and cellular DNA-polymerases are presented.


Apart from the 7-deazapurine compounds 2',3'-dideoxyribonucleosides have been prepared by anion glycosylation of corresponding nucleobases with an anomeric mixture of the halogenose 2² according to the formula schemes A and B. The halogenose was prepared in-situ from the corresponding lactol affording the protected nucleosides. They were desilylated and converted into the final molecules. The glycosylation position as well as the anomeric configuration was determined from ¹³C NMR in combination with 1D NOE difference spectroscopy.³



5-Aza-7-deazapurine- and 5-Aza-1,7-dideazapurine 2',3'-dideoxyribonucleosides (A)



8-Azapurine 2',3'-dideoxyribonucleoside (B)



7-Deazapurine 2',3'-didehydro-2',3'-dideoxynucleosides were prepared by deoxygenation via the elimination procedure depicted in the formula scheme C. Nucleophilic substitution of the 4-chloro

TABLE 1. ^{13}C NMR Data of Base-modified 2',3'-Dideoxynucleosides in $\text{DMSO}-d_6$ (rel. to int. TMS, purine numbering).

	C-1	C-2	C-4	C-5	C-6	C-7	C-8	C-1'	C-2'	C-3'	C-4'	C-5'
3a	-	152.6	150.3	100.1	158.7	102.9	116.9	83.0	31.5	26.5	80.6	63.4
3b	-	152.4	150.2	99.8	158.6	101.8	118.3	81.3	a)	69.3	84.0	59.9
7c	-	149.7	150.1	-	165.4	107.9	114.4	83.8	31.6	25.3	82.0	62.5
7e	97.3	156.1	144.0	-	155.9	107.3	117.3	84.9	32.0	25.0	82.4	62.3
4	-	152.6	150.5	100.1	158.6	102.2	116.9	87.4	126.1	133.6	87.0	63.6
8c	-	150.2	150.1	-	165.4	108.2	114.6	84.2	30.7	26.1	81.2	63.4
8e	97.4	156.1	144.2	-	155.9	107.6	117.5	85.3	31.0	26.0	81.5	63.4
10c	-	156.8	148.5	123.9	156.2	-	-	85.9	30.6	27.0	82.7	63.8
11c	-	156.9	148.5	124.0	156.1	-	-	86.3	30.1	26.5	81.7	63.1
12c	-	155.9	157.1	125.4	157.5	-	-	94.4	31.9	26.5	83.8	63.9
13c	-	156.7	157.1	125.5	157.5	-	-	94.7	31.3	25.6	82.3	63.1
14c	-	151.9	154.5	113.7	160.9	-	-	89.1	30.2	25.4	83.3	63.0
15c	-	151.8	154.6	113.6	160.9	-	-	89.5	29.4	25.3	81.8	63.0

a) superimposed by DMSO

substituent of 18 gave compound 4. Catalytic hydrogenation of 4 opens a new access to the 2',3'-dideoxynucleoside 3a. The threo-nucleoside 3b was synthesized from 17a as shown in the scheme.

7-Deazapurine 2',3'-Dideoxynucleosides (C)








TABLE 2. Inhibitory Data (IC_{50} ; μM) of 2',3'-Dideoxyribonucleoside Triphosphates against HIV Reverse Transcriptase (RT) and DNA Polymerases.

Compnd	IC_{50} (RT)	IC_{50} (DNA-Pol $_{\alpha}$)	IC_{50} (DNA-Pol $_{\gamma}$)
AZTTP	6.3	730	-
ddATP	0.45	-	-
ddGTP	0.2	-	-
21	0.53	970	-
22	0.12	680	1216
23	0.43	280	-
24	1000.		

From the series of base-modified dideoxynucleosides 5'-triphosphates were prepared in a one pot reaction.⁴ Selected compounds are depicted in the formula scheme. They were tested as inhibitors of HIV reverse transcriptase or DNA-polymerases α and γ . Inhibitory data are summarized in Table 2. Compounds 21-23 are 10-50 times more potent than AZTTP. Compound 22 shows high selectivity between HIV RT and cellular DNA-polymerases. The inhibitory action of the 7-deazapurine 2',3'-dideoxyribonucleosides demonstrates that N-7 is not required for RT binding. On the other hand, inhibitory studies with 24 revealed that N-1 is an essential enzymic binding position.



ACKNOWLEDGEMENT

We gratefully acknowledge financial support by the Bundesministerium für Forschung und Technologie.

REFERENCES

1. H. Mitsuya, S. Broder, *Proc. Natl. Acad. Sci. USA* **7**, 1911 (1986).
2. F. Seela, W. Bourgeois, H.-P. Muth, H. Rosemeyer, *Heterocycles* **29**, 2193 (1989).
3. H. Rosemeyer, G. Tóth, F. Seela, *Nucleos., Nucleotid.* **8**, 587 (1989).
4. F. Seela, W. Bourgeois, R. Gumbiowski, A. Mertens, H.-P. Muth, A. Röling, H. Rosemeyer (1990, in press).